<DOC>
	<DOC>NCT00099437</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy of a new dose of 500 mg Fulvestrant with the standard dose of 250 mg in postmenopausal women with oestrogen receptor positive advanced breast cancer who have failed on a previous endocrine treatment.</brief_summary>
	<brief_title>Comparison of Fulvestrant (FASLODEXâ„¢) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Breast Cancer has continued to grow after having received treatment with an antiestrogen hormonal treatment such as tamoxifen or an aromatase inhibitor Requiring hormonal treatment Postmenopausal women defined as a woman who has stopped having menstrual periods Evidence of positive estrogen receptor hormone sensitivity Written informed consent to participate in the trial Treatment with an investigational or nonapproved drug within one month An existing serious disease, illness, or condition that will prevent participation or compliance with study procedures A history of allergies to any active or inactive ingredients of Faslodex (i.e. castor oil) Treatment with more than one regimen of chemotherapy for advanced breast cancer Treatment with more than one regimen of hormonal treatment for advanced breast cancer</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Advanced Breast Cancer</keyword>
	<keyword>Metastatic Breast Cancer</keyword>
</DOC>